Frequently Asked Questions: USP Drug Classification System

  1. Why is USP committed to this effort?
  2. Why was the USP Drug Classification system created?
  3. What type of feedback did USP receive that lead to the development of the USP Drug Classification System?
  4. Through what forums did USP obtain feedback that lead to the development of the USP Drug Classification System?
  5. How will USP build off the successes and learning of the MMG?
  6. How is the USP Drug Classification System different than MMG?
  7. Does the USP Drug Classification System include all drugs from MMG?
  8. What sources were used to identify the drugs for the development of USP Drug Classification System?
  9. What was the approach to creating new USP Categories or Classes for USP Drug Classification System?
  10. When will USP Drug Classification System be finalized?

  1. Why is USP committed to this effort?

    USP’s objective standards-setting process, longstanding experience in convening experts and stakeholders, and ability to leverage its work on other classification systems uniquely enables USP to lead this effort. This experience and commitment to existing formulary work intuitively aligns with USP’s mission to improve lives through public standards and related programs that help ensure the quality, safety, and benefit of medicines.

    Back to Top

  2. Why was the USP Drug Classification system created?

    Stakeholder feedback indicated that the USP Medicare Model Guidelines (MMG) was being used beyond its intended use. The USP MMG was created specifically for Medicare Part D. Feedback highlighted the need to provide solutions to include prescriptions legally marketed beyond those specifically covered under the Medicare Part D benefit.

    Back to Top

  3. What type of feedback did USP receive that lead to the development of the USP Drug Classification System?

    Stakeholders identified the following needs for a comprehensive classification system that:

    • Includes commercially available prescription drugs
    • Extends use beyond Medicare Part D
    • Tailors to specific stakeholder uses
    • Updates more frequently, at least yearly
    • Cross-references other systems
    • Makes use of new technologies

    Back to Top

  4. Through what forums did USP obtain feedback that lead to the development of the USP Drug Classification System?

    USP has received feedback throughout the past 10 years. Examples include:

    Public Comment on Medicare Model Guidelines (MMG) v6.0 (2013)

    • Participants included patient advocacy groups, manufacturers, and health plans.
    • Stakeholder requested categorization of drugs related to obesity and infertility.
    • However, comments were out of scope for MMG revision1

    USP Stakeholder Meeting (2014)

    • Attendees included health plans, PBMs, MedPAC, and health policy analysts.
    • Stakeholder feedback identified short- and long-term opportunities.

    Stakeholder Interviews (2015)

    • Interviews were conducted with health plans, PBMs, drug information knowledge vendors, and pharmacy consultants.
    • Stakeholders identified additional features and technology needs.

    Back to Top

  5. How will USP build off the successes and learning of the MMG?

    The USP Drug Classification System is created by the same Expert Committee as the Medicare Model Guidelines and is developed with similar:

    • Guiding Principles
    • Taxonomy
    • Structure of the USP Categories and Classes

    Back to Top

  6. How is the USP Drug Classification System different than MMG?

    The chart below details the differences. Highlights of the major differences include:

    • Independent USP/stakeholder model
    • Revised annually
    • Expanded drug placement beyond Medicare Part D eligible drugs in USP Categories and Classes
    • Involvement of all stakeholders in public comment period beyond Medicare Part D
    • Flexibility for additional features in the system (beyond USP Categories and Classes)


    Proposed USP Drug Classification System Compared to USP MMG

     
    USP Medicare Model Guidelines 
    (USP MMG)
    USP Drug Classification System (USP DC)
     
    Developed through USP Expert Volunteers, Stakeholder Engagement, and Public Comment Processes

    Utilizes USP Guiding Principles for establishing Categories and Classes
     
    Contains USP Categories and Classes
     
    Provides Drug ExamplesPart D eligible drugs onlyCommon US outpatient drugs
    Implementation Tools: Mapping to RxNorm
     
    CMS FRF- MMG Alignment File (triannual)USP DC- RxNorm Alignment File (annual)
    Supports Medicare Part D requirementsN/A
    Stakeholder Focus in Public CommentMedicare StakeholdersAll Stakeholders 
    Revision CycleTri-annual*Annual
    Publication VersionUSP MMG v7.0Proposed first edition:
    USP DC 2017
    Publication DateFebruary 1, 2017February 1, 2017

    *Upon request of CMS

    Back to Top

  7. Does the USP Drug Classification System include all drugs from MMG?

    Yes, USP DC includes all drugs from MMG, along with a broader set of prescription medicines.

    Back to Top

  8. What sources were used to identify the drugs for the development of USP Drug Classification System?

    Many different resources were utilized including RXNORM, FDA NDC File, CCIIO crosswalk, stakeholder feedback, commercial formularies, and the Purple Book.

    Back to Top

  9. What was the approach to creating new USP Categories or Classes for USP Drug Classification System?

    The new USP Categories are created to encompass drugs that are included in commercial formularies beyond Medicare Part D. The new Categories created are Anti-obesity Agents, Infertility Agents, and Sexual Disorder Agents. The intended approach to creating new Categories or Classes is that they are broad enough to encompass future mechanism of actions and mindful of therapeutic options.

    Back to Top

  10. When will USP Drug Classification System be finalized?

    The proposed publication date for the USP Drug Classification System is February 1, 2017.

    Back to Top